# Partner Fund Management

> Partner Fund Management is a VC fund backing Biotechnology and Health Care. See 21 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 21
- Last investment: Jun 2020
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/522301
- Website: https://www.pfmlp.com

Partner Fund Management is a VC fund in San Francisco focused on Biotechnology and Health Care. Partner Fund Management provides services to pooled investment vehicles.

## Contacts

5 contacts available for Partner Fund Management. Shizune tracks 5 team members at Partner Fund Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/partner-fund-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 57% |
| Health Care | 11 | 52% |
| Medical | 10 | 48% |
| Biopharma | 4 | 19% |
| Medical Device | 3 | 14% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 8 | 38% |
| Series C | 4 | 19% |
| Series D | 2 | 10% |
| Series E | 2 | 10% |
| Seed | 1 | 5% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christopher James | Founder | 0 | https://shizune.co/investors/profile/chris-james |
| Ka-Wai To | Investment Analyst | 0 | https://shizune.co/investors/profile/kawai-to |
| Manish N Chitnis | Risk Manager | 0 | https://shizune.co/investors/profile/manish-n-chitnis |
| Mark Karvosky | Partner | 0 | https://shizune.co/investors/profile/mark-karvosky |
| William R. Goodell | Chief Operating Officer | 0 | https://shizune.co/investors/profile/william-r-goodell |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Shattuck Labs | Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with TakedaPharmaceuticals.Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients. | $118M | Series B | Jun 15, 2020 |  |
| Pulmonx | Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), theChartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date. | $66M | Series H | May 05, 2020 |  |
| Apella Technology | Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California. | $3M | Seed | Apr 01, 2020 |  |
| Outset Medical | Outset Medical is a pioneering medical technology company that manufactures medical equipment. The company reimagining dialysis for patients and health care providers. The innovative, compact, user-friendly Tablo Hemodialysis System can deliver both acute and chronic dialysis, wherever you need it.Through the versatile, all-in-one TabloHemodialysis System, they are using innovative technology to drive service model innovation, aimed at reducing cost and transforming the patient care experience. The system comes equipped with wireless data, sensor-based automation, and an animated touchscreen to make the system as easy to use as possible. | $125M | Series E | Feb 05, 2020 |  |
| Avidity Biosciences | Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $100M | Series C | Nov 13, 2019 |  |
| Karuna Therapeutics | Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. | $68M | Series B | Mar 18, 2019 |  |
| Auris Health | Auris Health engages in the development of robotics technology for medical applications. The company designs a novel dual-arm micro-surgical system for ophthalmic surgery. The company focuses on transforming medical intervention by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform. It wasfounded in 2007 and headquartered in Redwood City, California. | $220M | Series E | Nov 28, 2018 |  |
| Outset Medical | Outset Medical is a pioneering medical technology company that manufactures medical equipment. The company reimagining dialysis for patients and health care providers. The innovative, compact, user-friendly Tablo Hemodialysis System can deliver both acute and chronic dialysis, wherever you need it.Through the versatile, all-in-one TabloHemodialysis System, they are using innovative technology to drive service model innovation, aimed at reducing cost and transforming the patient care experience. The system comes equipped with wireless data, sensor-based automation, and an animated touchscreen to make the system as easy to use as possible. | $132M | Series D | Aug 28, 2018 |  |
| Cytrellis Biosystems | Cytrellis Biosystems is a clinical stage medical technology company that designs and develops medical device for dermatology, scar reduction, and aesthetic medicine. Its devices are designed to remove sagging skin associated with aging without surgery or scarring, providing aesthetic practitioners an unprecedented ability to improve age relatedchanges in skin.Cytrellis Biosystems was founded in 2011 and is based in Boston, Massachusetts. | $28.5M | Series B | Jun 05, 2018 |  |
| UNITY Biotechnology | Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. | $55M | Series C | Mar 19, 2018 |  |

10 of 21 investments shown.

## Co-investors
- [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 9 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 6 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 5 deals together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 4 deals together
- [Wellington Management](https://shizune.co/investors/profile/wellington-management) — VC Fund, 4 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Partner Fund Management invest in?

Partner Fund Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Partner Fund Management?

Public channels for Partner Fund Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Partner Fund Management?

The team at Partner Fund Management includes Christopher James (Founder), Ka-Wai To (Investment Analyst) and Manish N Chitnis (Risk Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co